BioLife Solutions (NASDAQ:BLFS) Insider Karen Foster Sells 419 Shares

Key Points

• Insider Transaction: Karen Foster, an insider at BioLife Solutions, sold 419 shares at an average price of $27.36, totaling $11,463.84, decreasing her ownership stake by 0.22%.
• Stock Performance: BioLife Solutions' stock currently trades at $27.66 with a market cap of $1.32 billion, reflecting a trading volume below its average, and has seen a 52-week low of $19.10 and a high of $29.55.
• Quarterly Earnings Results: The company's last earnings report showed a loss of ($0.33) per share, significantly missing analyst expectations, but revenue exceeded forecasts at $25.42 million.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Karen Foster sold 419 shares of the business's stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $27.36, for a total transaction of $11,463.84. Following the completion of the sale, the insider directly owned 193,253 shares in the company, valued at $5,287,402.08. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock traded up $0.24 on Tuesday, reaching $27.66. The company had a trading volume of 346,859 shares, compared to its average volume of 465,156. The firm's 50 day moving average price is $25.21 and its two-hundred day moving average price is $23.33. The firm has a market cap of $1.32 billion, a PE ratio of -230.48 and a beta of 1.95. BioLife Solutions, Inc. has a 52-week low of $19.10 and a 52-week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The company had revenue of $25.42 million during the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLFS. Rhumbline Advisers grew its holdings in BioLife Solutions by 0.7% during the 1st quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after acquiring an additional 566 shares in the last quarter. GAMMA Investing LLC grew its holdings in BioLife Solutions by 18.6% during the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after acquiring an additional 663 shares in the last quarter. SG Americas Securities LLC grew its holdings in BioLife Solutions by 21.6% during the 1st quarter. SG Americas Securities LLC now owns 19,136 shares of the medical equipment provider's stock worth $437,000 after acquiring an additional 3,405 shares in the last quarter. Peregrine Capital Management LLC grew its holdings in BioLife Solutions by 3.5% during the 1st quarter. Peregrine Capital Management LLC now owns 364,446 shares of the medical equipment provider's stock worth $8,324,000 after acquiring an additional 12,241 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in BioLife Solutions by 6.2% during the 1st quarter. Principal Financial Group Inc. now owns 259,488 shares of the medical equipment provider's stock worth $5,927,000 after acquiring an additional 15,241 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

Analyst Upgrades and Downgrades

BLFS has been the topic of several recent research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Stephens initiated coverage on shares of BioLife Solutions in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 target price on the stock. Finally, Zacks Research downgraded shares of BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.